These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23085981)

  • 1. DNA reactivity as a mode of action and its relevance to cancer risk assessment.
    Preston RJ
    Toxicol Pathol; 2013 Feb; 41(2):322-5. PubMed ID: 23085981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
    Preston RJ
    Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
    McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
    Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
    Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
    Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of in vivo mutation data can inform cancer risk assessment.
    Moore MM; Heflich RH; Haber LT; Allen BC; Shipp AM; Kodell RL
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):151-61. PubMed ID: 18321622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating genotoxicity data to identify a mode of action and its application in estimating cancer risk at low doses: A case study involving carbon tetrachloride.
    Eastmond DA
    Environ Mol Mutagen; 2008 Mar; 49(2):132-41. PubMed ID: 18213651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chloroform mode of action: implications for cancer risk assessment.
    Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A classification framework and practical guidance for establishing a mode of action for chemical carcinogens.
    Butterworth BE
    Regul Toxicol Pharmacol; 2006 Jun; 45(1):9-23. PubMed ID: 16530901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Aminobiphenyl and DNA reactivity: case study within the context of the 2006 IPCS Human Relevance Framework for Analysis of a cancer mode of action for humans.
    Cohen SM; Boobis AR; Meek ME; Preston RJ; McGregor DB
    Crit Rev Toxicol; 2006; 36(10):803-19. PubMed ID: 17118730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of mode-of-action considerations in human cancer risk assessment.
    Williams GM
    Toxicol Lett; 2008 Aug; 180(2):75-80. PubMed ID: 18588958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive approach for integration of toxicity and cancer risk assessments.
    Butterworth BE; Bogdanffy MS
    Regul Toxicol Pharmacol; 1999 Feb; 29(1):23-36. PubMed ID: 10051416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IPCS framework for analyzing the relevance of a cancer mode of action for humans.
    Boobis AR; Cohen SM; Dellarco V; McGregor D; Meek ME; Vickers C; Willcocks D; Farland W
    Crit Rev Toxicol; 2006; 36(10):781-92. PubMed ID: 17118728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutagenicity of bromate: implications for cancer risk assessment.
    Moore MM; Chen T
    Toxicology; 2006 Apr; 221(2-3):190-6. PubMed ID: 16460860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the mode of action framework for mutagenic carcinogens case study II: chromium (VI).
    McCarroll N; Keshava N; Chen J; Akerman G; Kligerman A; Rinde E
    Environ Mol Mutagen; 2010 Mar; 51(2):89-111. PubMed ID: 19708067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-reactive carcinogens: mode of action and human cancer hazard.
    Preston RJ; Williams GM
    Crit Rev Toxicol; 2005; 35(8-9):673-83. PubMed ID: 16417034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical carcinogenesis.
    Cohen SM; Arnold LL
    Toxicol Sci; 2011 Mar; 120 Suppl 1():S76-92. PubMed ID: 21147961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments.
    Butterworth BE; Conolly RB; Morgan KT
    Cancer Lett; 1995 Jun; 93(1):129-46. PubMed ID: 7600540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postulated carbon tetrachloride mode of action: a review.
    Manibusan MK; Odin M; Eastmond DA
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2007; 25(3):185-209. PubMed ID: 17763046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.